Products for Research Use Only

Fusicoccin

CAT: 0804-HY-122815Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-122815Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fusicoccin (Fusicoccin A), a fungal pytotoxin, is a stabilizer of specific 14-3-3 protein-protein interactions. Fusicoccin sabilizes H+-ATPase/14-3-3 cmplex in pants, maintaining the enzyme in activated state. Fusicoccin also stabilizes 14-3-3 protein interactions with binding partners containing a C-terminal 14-3-3 recognition motif (a mode 3 motif), such as ERα, GPIbα, TASK3, CTFR, and p53. Fusicoccin induces apoptosis in cancer cells and has anticancer activity[1][2][3][4].
CAS Number
20108-30-9
Product Name Alternative
Fusicoccin A
UNSPSC
12352005
Target
Apoptosis
Type
Natural Products
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fusicoccin.html
Purity
96.30
Solubility
10 mM in DMSO
Smiles
C[C@](/C=C([C@H]1COC)\[C@](CC1)([H])[C@H]2C)([C@H]3O)C([C@H]([C@@H]2O)O[C@@H](O[C@@H]4COC(C)(C)C=C)[C@@H]([C@H]([C@@H]4O)OC(C)=O)O)=C(C3)[C@H](C)COC(C)=O
Molecular Formula
C36H56O12
Molecular Weight
680.82
References & Citations
[1]Camoni L, et al. The phytotoxin fusicoccin, a selective stabilizer of 14-3-3 interactions?. IUBMB Life. 2013;65 (6) :513-517.|[2]Doveston RG, et al. Small-molecule stabilization of the p53-14-3-3 protein-protein interaction. FEBS Lett. 2017;591 (16) :2449-2457.|[3]Kaplan A, et al. Small-Molecule Stabilization of 14-3-3 Protein-Protein Interactions Stimulates Axon Regeneration. Neuron. 2017;93 (5) :1082-1093.e5.|[4]Bury M, et al. Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases. Transl Oncol. 2013;6 (2) :112-123.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported